Advertisement Pharmaceutical Business review - Page 296 of 5255 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
January 5, 2026

Samsung Bioepis initiates Byooviz commercialisation in Europe

Samsung Bioepis has started direct commercialisation of Byooviz, a biosimilar to Genentech’s Lucentis (ranibizumab), in Europe.

The CHMP issued a positive opinion for the pre-filled syringe. Credit: Me dia / Shutterstock.com.